Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 2.
Journal
RSC medicinal chemistry
ISSN: 2632-8682
Titre abrégé: RSC Med Chem
Pays: England
ID NLM: 101759460
Informations de publication
Date de publication:
17 Dec 2020
17 Dec 2020
Historique:
received:
25
05
2020
accepted:
07
08
2020
entrez:
7
6
2021
pubmed:
8
6
2021
medline:
8
6
2021
Statut:
epublish
Résumé
Building on our previously-reported novel tricyclic topoisomerase inhibitors (NTTIs), we disclose the discovery of REDX07965, which has an MIC
Identifiants
pubmed: 34095845
doi: 10.1039/d0md00175a
pii: d0md00175a
pmc: PMC8126889
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1379-1385Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
All authors were or are employees of Redx Pharma and may hold shares or share options in the company.
Références
J Antimicrob Chemother. 2016 Jul;71(7):1905-13
pubmed: 27032669
J Biomol Screen. 2013 Apr;18(4):441-52
pubmed: 23264450
Org Lett. 2006 Nov 9;8(23):5231-4
pubmed: 17078685
Bioorg Med Chem Lett. 2007 Mar 1;17(5):1312-20
pubmed: 17196390
ACS Chem Biol. 2014 Dec 19;9(12):2895-904
pubmed: 25310082
J Med Chem. 2006 Nov 2;49(22):6435-8
pubmed: 17064062
Bioorg Med Chem Lett. 2008 Sep 15;18(18):5087-90
pubmed: 18752951
J Antimicrob Chemother. 1996 Feb;37(2):365-9
pubmed: 8707749